Hailey Connolly
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Hailey Connolly has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Namarata G. Jain
Division of Pediatric Nephrology, Department of Pediatrics Joseph M. Sanzari Children's Hospital at Hackensack University Medical Center Hackensack New Jersey USA
2 shared publications - Aftab Chishti
Department of Pediatrics University of Kentucky Lexington Kentucky USA
1 shared publication - Ally Watson
Division of Pediatric Nephrology, Department of Pediatrics Joseph M. Sanzari Children's Hospital at Hackensack University Medical Center Hackensack New Jersey USA
1 shared publication - Asifhusen Mansuri
Department of Pediatrics, Children's Hospital of Georgia, Medical college of Georgia Augusta University Augusta Georgia USA
1 shared publication - Guillermo Hidalgo
Hackensack Meridian School of Medicine
1 shared publication H. Tawadrous
Department of Pediatrics Connecticut Children's Medical Center Hartford Connecticut USA
1 shared publication
Latest Publications
- Open Access
- 18 July 2025
- Published by Wiley in Pediatric Transplantation
- Vol. 29 (5) , e70130
Provider Perspectives on the Role of Hypotension in Pediatric Kidney Transplant: A Pediatric Nephrology Research Consortium Study
Background: The lack of a consistent definition for hypotension in the pediatric population complicates the study of hypotension in pediatric kidney transplant recipients. Additionally, there is limited data to guide the management of hypotension in these patients both before and after transplantation. Methods: A 10‐question survey was distributed to pediatric nephrologists. The survey data was analyzed using descriptive statistical methods without hypothesis testing. Results: A total of 25 respondents completed the survey, revealing significant variability in the definitions of hypotension used and in the management approaches for hypotension during the pre‐ and posttransplant periods. Conclusions: There is significant variability in practice patterns regarding the management of hypotension in pediatric transplant recipients. This highlights the need for further research to evaluate the prevalence of chronic hypotension in the pediatric ESKD population and to assess its impact on transplant outcomes.
- 18 July 2025
- Published by Wiley in Pediatric Transplantation
- Vol. 29 (5) , e70130
Open AccessProvider Perspectives on the Role of Hypotension in Pediatric Kidney Transplant: A Pediatric Nephrology Research Consortium Study
Background: The lack of a consistent definition for hypotension in the pediatric population complicates the study of hypotension in pediatric kidney transplant recipients. Additionally, there is limited data to guide the management of hypotension in these patients both before and after transplantation. Methods: A 10‐question survey was distributed to pediatric nephrologists. The survey data was analyzed using descriptive statistical methods without hypothesis testing. Results: A total of 25 respondents completed the survey, revealing significant variability in the definitions of hypotension used and in the management approaches for hypotension during the pre‐ and posttransplant periods. Conclusions: There is significant variability in practice patterns regarding the management of hypotension in pediatric transplant recipients. This highlights the need for further research to evaluate the prevalence of chronic hypotension in the pediatric ESKD population and to assess its impact on transplant outcomes.
- 9 June 2025
- Published by Wiley in Pediatric Transplantation
- Vol. 29 (5) , e70116
Daratumumab for Treatment of Acute Antibody‐Mediated Rejection in a Pediatric Kidney Transplant Recipient
Background: Daratumumab, an anti‐CD38 monoclonal antibody, has shown efficacy as a potential treatment for antibody‐mediated rejection (ABMR) following kidney transplantation in adults. Methods: We present a case demonstrating the use of daratumumab for the management of ABMR in a pediatric kidney transplant recipient. Results: The patient underwent a living‐unrelated donor renal transplant with a post‐transplant course complicated by active ABMR. The patient received a total of four daratumumab infusions with a subsequent decrease in serum creatinine, serum donor‐specific antibody levels, and donor‐derived cell‐free DNA (dd‐cfDNA), which remained low 1 year following treatment. Conclusions: Daratumumab may be a promising treatment consideration for the management of ABMR in pediatric patients following renal transplantation, though further research is needed to better understand its efficacy and side effects. DD‐cfDNA may also be a promising tool to monitor treatment response in conjunction with more traditional methods.
- 9 June 2025
- Published by Wiley in Pediatric Transplantation
- Vol. 29 (5) , e70116
Daratumumab for Treatment of Acute Antibody‐Mediated Rejection in a Pediatric Kidney Transplant Recipient
Background: Daratumumab, an anti‐CD38 monoclonal antibody, has shown efficacy as a potential treatment for antibody‐mediated rejection (ABMR) following kidney transplantation in adults. Methods: We present a case demonstrating the use of daratumumab for the management of ABMR in a pediatric kidney transplant recipient. Results: The patient underwent a living‐unrelated donor renal transplant with a post‐transplant course complicated by active ABMR. The patient received a total of four daratumumab infusions with a subsequent decrease in serum creatinine, serum donor‐specific antibody levels, and donor‐derived cell‐free DNA (dd‐cfDNA), which remained low 1 year following treatment. Conclusions: Daratumumab may be a promising treatment consideration for the management of ABMR in pediatric patients following renal transplantation, though further research is needed to better understand its efficacy and side effects. DD‐cfDNA may also be a promising tool to monitor treatment response in conjunction with more traditional methods.
- Open Access
- 4 June 2024
- Published by Wiley in Pediatric Transplantation
- Vol. 28 (5) , e14790
Probiotic use in pediatric kidney transplant recipients: What are current practices, and are they evidence‐based? A pediatric nephrology research consortium study
Background: Probiotics are living microorganisms that may confer health benefits to their host if administered in sufficient quantities. However, data on the use of probiotics in transplant recipients are scarce.Method: This multi‐center survey of pediatric nephrologists aimed to examine variations in practice regarding the use of probiotics in pediatric kidney transplant recipients. The survey was conducted via a 10‐item questionnaire (developed in Survey Monkey) administered to pediatric nephrologists participating in the Pediatric Nephrology Research Consortium meeting in April 2023.Results: Sixty‐four pediatric nephrologists completed the survey. Twenty‐seven (42.2%) respondents reported having prescribed probiotics to pediatric kidney transplant recipients. The primary reason for probiotic use was the treatment of antibiotic‐associated diarrhea (n = 20), with other reasons including recurrent Clostridium difficile infection (n = 15), general gut health promotion (n = 12), recurrent urinary tract infections (n = 8), and parental request (n = 1). Of those who prescribed probiotics, 48.1% held them during periods of neutropenia and 14.8% during central venous line use. Of the 64 respondents, 20 reported the lack of safety data as a concern for using probiotics in kidney transplant recipients.Conclusion: Pediatric nephrologists are increasingly prescribing probiotics to pediatric kidney transplant recipients; nevertheless, substantial practice variations exist. The paucity of safety data is a significant deterrent to probiotic use in this population.
- 4 June 2024
- Published by Wiley in Pediatric Transplantation
- Vol. 28 (5) , e14790
Open AccessProbiotic use in pediatric kidney transplant recipients: What are current practices, and are they evidence‐based? A pediatric nephrology research consortium study
Background: Probiotics are living microorganisms that may confer health benefits to their host if administered in sufficient quantities. However, data on the use of probiotics in transplant recipients are scarce.Method: This multi‐center survey of pediatric nephrologists aimed to examine variations in practice regarding the use of probiotics in pediatric kidney transplant recipients. The survey was conducted via a 10‐item questionnaire (developed in Survey Monkey) administered to pediatric nephrologists participating in the Pediatric Nephrology Research Consortium meeting in April 2023.Results: Sixty‐four pediatric nephrologists completed the survey. Twenty‐seven (42.2%) respondents reported having prescribed probiotics to pediatric kidney transplant recipients. The primary reason for probiotic use was the treatment of antibiotic‐associated diarrhea (n = 20), with other reasons including recurrent Clostridium difficile infection (n = 15), general gut health promotion (n = 12), recurrent urinary tract infections (n = 8), and parental request (n = 1). Of those who prescribed probiotics, 48.1% held them during periods of neutropenia and 14.8% during central venous line use. Of the 64 respondents, 20 reported the lack of safety data as a concern for using probiotics in kidney transplant recipients.Conclusion: Pediatric nephrologists are increasingly prescribing probiotics to pediatric kidney transplant recipients; nevertheless, substantial practice variations exist. The paucity of safety data is a significant deterrent to probiotic use in this population.